Publications

Detailed Information

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial

Cited 5 time in Web of Science Cited 6 time in Scopus
Authors

Triulzi, Tiziana; Bianchini, Giampaolo; Di Cosimo, Serena; Pienkowski, Tadeusz; Im, Young-Hyuck; Bianchi, Giulia Valeria; Galbardi, Barbara; Dugo, Matteo; De Cecco, Loris; Tseng, Ling-Ming; Liu, Mei-Ching; Bermejo, Begoña; Semiglazov, Vladimir; Viale, Giulia; de la Haba-Rodriguez, Juan; Oh, Do-Youn; Poirier, Brigitte; Valagussa, Pinuccia; Gianni, Luca; Tagliabue, Elda

Issue Date
2022-06
Publisher
Elsevier BV
Citation
Molecular Oncology, Vol.16 No.12, pp.2355-2366
Abstract
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage therapy, are needed. Herein, we evaluated the 41-gene classifier trastuzumab advantage risk model (TRAR) as a predictive marker for patients enrolled in the NeoSphere trial. TRAR scores were computed from RNA of 350 pre- and 166 post-treatment tumor specimens. Overall, TRAR score was significantly associated with pathological complete response (pCR) rate independently of other predictive clinico-pathological variables. Separate analyses according to estrogen receptor (ER) status showed a significant association between TRAR score and pCR in ER-positive specimens but not in ER-negative counterparts. Among ER-positive BC patients not achieving a pCR, those with TRAR-low scores in surgical specimens showed a trend for lower distant event-free survival. In conclusion, in HER2-positive/ER-positive BC, TRAR is an independent predictor of pCR and represents a promising tool to select patients responsive to anti-HER2-based neoadjuvant therapy and to assist treatment escalation and de-escalation strategies in this setting.
ISSN
1574-7891
URI
https://hdl.handle.net/10371/212744
DOI
https://doi.org/10.1002/1878-0261.13141
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area DNA 손상 반응 타겟 물질의 면역조절 효과, Effect of DNA damage response target substances on immunomodulatory action, Efficacy and biomarker validation studies of targeted therapeutics, Resistance mechanisms according to targeted therapeutics, 표적 항암제 내성 기전 연구, 표적 항암제의 효과 검증 및 바이오마커 규명

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share